Table Filtering
Submissions
GlyTouCan
Glycan Structure Repository
GlyComb
Glycoconjugate Repository
GlycoPOST
Glycomics MS raw data Repository
UniCarb-DR
Glycomics MS Repository for glycan annotations from GlycoWorkbench
All Resources
Genes / Proteins / Lipids Glycans / Glycoconjugates Glycomes Pathways / Interactions / Diseases / Organisms
GlycoNAVI Proteins
GlycoNAVI-Proteins is dataset of glycan and protein information. This is the content of GlycoNAVI.
| Source | Last Updated |
|---|---|
| GlycoNAVI Proteins | September 04, 2024 |
| PDB ID ▼ | UniProt ID | Title | Descriptor |
|---|---|---|---|
| 8D2U | Q6DEJ6 | Zebrafish MFSD2A isoform B in inward open ligand 1A conformation | |
| 8D2U | 8D2U | Zebrafish MFSD2A isoform B in inward open ligand 1A conformation | |
| 8D2T | Q6DEJ6 | Zebrafish MFSD2A isoform B in inward open ligand-free conformation | |
| 8D2T | 8D2T | Zebrafish MFSD2A isoform B in inward open ligand-free conformation | |
| 8D2S | Q6DEJ6 | Zebrafish MFSD2A isoform B in inward open ligand bound conformation | |
| 8D2S | 8D2S | Zebrafish MFSD2A isoform B in inward open ligand bound conformation | |
| 8D21 | Q6WG00 | Cryo-EM structure of the VRC321 clinical trial, vaccine-elicited, human antibody 1B06 in complex with a stabilized NC99 HA trimer | |
| 8D21 | Q289M7 | Cryo-EM structure of the VRC321 clinical trial, vaccine-elicited, human antibody 1B06 in complex with a stabilized NC99 HA trimer | |
| 8D21 | 8D21 | Cryo-EM structure of the VRC321 clinical trial, vaccine-elicited, human antibody 1B06 in complex with a stabilized NC99 HA trimer | |
| 8D0Z | P0DTC2 | S728-1157 IgG in complex with SARS-CoV-2-6P-Mut7 Spike protein (focused refinement) | |
| 8D0Z | 8D0Z | S728-1157 IgG in complex with SARS-CoV-2-6P-Mut7 Spike protein (focused refinement) | |
| 8D0Y | 8D0Y | Crystal Structure of HIV-1 BG505 SOSIPv8 Trimer in Complex with CD4bs targeting antibody 21N13 and interface targeting antibody 35O22 at 4.7 Angstrom | |
| 8D0X | Q9Y231 | Human FUT9 bound to LNnT | |
| 8D0W | Q9Y231 | Human FUT9 bound to H-Type 2 | |
| 8D0U | Q9Y231 | Human FUT9 bound to GDP | |
| 8D0S | Q9Y231 | Human FUT9 bound to GDP and LNnT | |
| 8D0R | Q9Y231 | Human FUT9 bound to GDP and H-Type 2 | |
| 8D0Q | Q9Y231 | Human FUT9 bound to GDP-CF3-Fucose and H-Type 2 | |
| 8D0P | Q9Y231 | Human FUT9, unliganded | |
| 8D0O | Q9Y231 | Human alpha1,3-fucosyltransferase FUT9, heavy atom derivative | |
| 8CZZ | A0A6C0ZY47 | Cryo-EM structure of T/F100 SOSIP.664 HIV-1 Env trimer with LMHS mutations in complex with Temsavir, 8ANC195, and 10-1074 | |
| 8CZZ | 8CZZ | Cryo-EM structure of T/F100 SOSIP.664 HIV-1 Env trimer with LMHS mutations in complex with Temsavir, 8ANC195, and 10-1074 | |
| 8CYH | 8CYH | Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics | |
| 8CYH | Q13421 | Novel Anti-Mesothelin Antibodies Enable Crystallography of the Intact Mesothelin Ectodo- main and Engineering of Potent, T cell-engaging Bispecific Therapeutics | |
| 8CYB | P0DTC2 | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-8 | |
| 8CYB | 8CYB | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 1-8 | |
| 8CYA | P0DTC2 | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-67 | |
| 8CYA | 8CYA | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-67 | |
| 8CY7 | P0DTC2 | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-34 | |
| 8CY7 | 8CY7 | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-34 | |
| 8CXN | P0DTC2 | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-57 | |
| 8CXN | 8CXN | SARS-CoV-2 Spike protein in complex with a pan-sarbecovirus nanobody 2-57 | |
| 8CXI | A0A142DS37 | Structures of Zika Virus in Complex with Antibodies Targeting E Dimer Epitopes and Basis for Neutralization Efficacy | |
| 8CXI | Q9H9E1 | Structures of Zika Virus in Complex with Antibodies Targeting E Dimer Epitopes and Basis for Neutralization Efficacy | |
| 8CXI | A0A1S6LXE0 | Structures of Zika Virus in Complex with Antibodies Targeting E Dimer Epitopes and Basis for Neutralization Efficacy | |
| 8CXI | 8CXI | Structures of Zika Virus in Complex with Antibodies Targeting E Dimer Epitopes and Basis for Neutralization Efficacy | |
| 8CX3 | Q13421 | Crystal structure of full-length mesothelin | |
| 8CWV | P0DTC2 | Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutralizing nanobody 2-31 and a human antibody CC12.1 Fab | |
| 8CWV | 8CWV | Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutralizing nanobody 2-31 and a human antibody CC12.1 Fab | |
| 8CWU | P0DTC2 | Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutralizing nanobody 1-21 | |
| 8CWU | 8CWU | Crystal structure of SARS-CoV-2 spike protein receptor-binding domain in complex with a cross-neutralizing nanobody 1-21 | |
| 8CWK | 8CWK | Fab arm of antibodies 4G1-C2 and 10G4 bound to CoV-2 receptor binding domain (RBD) | |
| 8CWK | Q6GMX0 | Fab arm of antibodies 4G1-C2 and 10G4 bound to CoV-2 receptor binding domain (RBD) | |
| 8CWK | P0DTC2 | Fab arm of antibodies 4G1-C2 and 10G4 bound to CoV-2 receptor binding domain (RBD) | |
| 8CWJ | 8CWJ | Fab arms of antibodies 4C12-B12 and CR3022 bound to pangolin receptor binding domain (pRBD) | |
| 8CWJ | A0A7D6TQ96 | Fab arms of antibodies 4C12-B12 and CR3022 bound to pangolin receptor binding domain (pRBD) | |
| 8CWI | P0DTC2 | Fab arm of antibody 10G4 bound to CoV-2 receptor binding domain (RBD) | |
| 8CWI | 8CWI | Fab arm of antibody 10G4 bound to CoV-2 receptor binding domain (RBD) | |
| 8CWH | P00698 | 200us Temperature-Jump (Dark2) XFEL structure of Lysozyme Bound to N,N'-diacetylchitobiose | |
| 8CWG | P00698 | 200us Temperature-Jump (Dark1) XFEL structure of Lysozyme Bound to N,N'-diacetylchitobiose |
